Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, “Complications Combat”
May 24, 2013

For Non-U.S. and Non-UK media

Boehringer Ingelheim and Eli Lilly & Company have today launched an educational digital game for type 2 diabetes called Complications Combat. The game, available for desktop and iPad users, is designed to raise awareness of the many complications associated with type 2 diabetes"...

Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research
May 22, 2013

Quintiles is the industry leader that best differentiates itself on service quality in Phase II/III clinical research, according to 157 pharmaceutical and biotechnology professionals who responded to Industry Standard Research’s (ISR) 2013"......

Covidien Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue and Significantly Reduces Disease Progression
May 22, 2013

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that results from a prospective, multicenter, randomized, controlled clinical trial show that endoscopic ablation therapy using the Barrx™ RF Ablation System is effective at eliminating Barrett’s esophagus, a pre-cancerous condition of"...

Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response
May 21, 2013

• Tiotropium delivered by the Respimat® SoftMistTM Inhaler increases time to first severe exacerbation and first episode of asthma worsening across a broad spectrum of patients who remain symptomatic despite at least ICS/LABA therapy
• The improvements in lung function with tiotropium were specific to asthma patients; as a co-morbid condition, chronic obstructive pulmonary disease (COPD) was excluded in this trial

For Media outside the U.S.,"...

Arthur D. Little creates strategy for healthcare launch excellence
May 21, 2013

After years of low productivity, R&D in leading pharmaceutical and biotech companies is starting to deliver on its promises; the number of New Molecular Entities (NMEs) approved by the US FDA has leveled out and biotech companies’ share prices are rising, indicating profitable business models. Now is the time for launch. Arthur D. Little’s (ADL) latest viewpoint, ‘Launch excellence for new medicines,’ assesses the key success factors for"...

New Study Reports Key Findings for the ABThera™ Open Abdomen Negative Pressure Therapy System
May 17, 2013

Kinetic Concepts, Inc. announced today that ABThera™ Open Abdomen Negative Pressure Therapy System (ABThera™ OA NPT) was associated with significantly improved patient outcomes compared to traditional Barker’s vacuum-packing technique (BVPT) in trauma and surgical patients studied. Results of the observational study, “Prospective Study Examining Clinical Outcomes Associated with a Negative Pressure Wound Therapy System and Barker’s Vacuum Packing Technique” were published in"......

Quintiles Announces Completion of Initial Public Offering of 27,236,841 Shares of Common Stock
May 17, 2013

Quintiles today announced the completion of its initial public offering of 27,236,841 shares of its common stock at a price to the public of $40.00 per share. Quintiles offered and sold 13,125,000 shares of common stock in the offering and selling shareholders offered and sold 14,111,841 shares of common stock in the offering, including 3,552,631 shares that were offered and sold by the selling shareholders pursuant to the full exercise of the underwriters’"...

ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC
May 16, 2013

Growing body of clinical data supports superiority of the irreversible ErbB Family Blocker afatinib* over standard chemotherapy (with combination of cisplatin and gemcitabine or pemetrexed) for first-line treatment of patients with EGFR-mutation positive advanced NSCLC

First set of Phase III results unveiled from"...

Merck Serono and Quintiles Announce Innovative Clinical Development Partnership
May 16, 2013

Merck Serono, a division of Merck, Darmstadt, Germany, and Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, today announced a new, five-year clinical development agreement. This strategic collaboration is the first-of-its-kind between a biopharmaceutical company and a biopharmaceutical services provider, creating a comprehensive process that integrates the expertise and experience from both organizations into a single, well-aligned clinical development engine.

...

New evidence establishes EPA as highly predictive of skin graft failure and supports the utility of Systagenix WOUNDCHEK™ Protease Status point of care test in this application
May 15, 2013

New evidence presented on Wednesday 15th May 2013 at the European Wound Management Association (EWMA)’s conference in Copenhagen, revealed that elevated protease activity (EPA) was detected in almost half the wounds (43%) that resulted in skin graft failure1.

......